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Poster Session II S273therapies. Current therapy includes corticosteroids and immunosup-
pression. Azithromycin has been used to manage BO following lung
transplantation; however it has been reported in fewHSCT patients.
We report our experience in 46 patients receiving azithromycin for
BO.
Methods: IRB approval and patient consent were obtained prior to
review of electronic medical records and theMayo Clinic HSCT da-
tabase. All adult patients who received a HSCT from 1/1/00 to 8/1/
09 and received azithromycin were included. Patients were excluded
if they refused consent for use of medical records for research, re-
ceived azithromycin for prophylaxis or treatment of infection, or
did notmeet criteria for BO according to the 2001 diagnostic criteria
for BO in lung transplantation. BO stage was based on PFTs follow-
ing these criteria. Baseline demographic characteristics and clinical
endpoints were collected including: change in PFTs, therapy re-
ceived, and survival following BO diagnosis.
Results: From 1/1/00 to 8/1/09, 388 patients underwent alloge-
neic HSCT at Mayo Clinic Rochester; 46 received azithromycin
for BO. 342 patients were excluded: consent refused (n5 1), no
azithromycin (n5 306), azithromycin for treatment of infection
(n5 27), azithromycin for prophylaxis of infection (n5 6), BO
stage 0 (n5 2). Primary diagnosis included AML/MDS (n5 21),
ALL (n5 9), MM (n5 5), CLL (n5 4), CML (n5 3), lymphoma
(n5 3), CMML (n5 1). Median age at diagnosis of BO was 48
years (range 19-68). 25/46 (54%) received a MUD allogeneic
HSCT. 17/46 (37%) received reduced intensity conditioning.
24/46 (52%) received. 1200 cGy TBI. Median time from trans-
plant to BO diagnosis was 363 days (range 98-1822 days). Azithro-
mycin dosing regimens ranged from 250 mg thrice weekly to
500 mg daily. 30 patients received systemic corticosteroids, 31 re-
ceived inhaled corticosteroids, 14 received ECP, and 5 receivedTable 1. Pulmonary Function Tests in Patients with Bronchiolitis Obliterans
Pre-transplant At diagnosis of BO 1 month 3 months 6 months 9 months 12 months
FEV1 891/-15 (n5 46) 551/-16 (n5 46) 631/-22 (n5 39) 641/-23 (n5 28) 581/-26 (n5 28) 631/-27 (n5 17) 521/-19 (n5 18)
FEF 25-75 831/-32 (n5 46) 441/-30 (n5 46) 571/-42 (n5 39) 531/-29 (n5 28) 501/-36 (n5 28) 571/-44 (n5 17) 411/-33 (n5 18)
DLCO 801/-16 (n5 41) 561/-12 (n5 39) 601/-15 (n5 31) 621/-15 (n5 21) 601/-15 (n5 16) 611/-16 (n5 12) 601/-15 (n5 16)
BO Stage
0 0 5 2 3 3 0
Potential BO 3 6 5 5 2 1
1 9 5 6 3 4 4
2 16 14 8 5 2 5
3 18 9 7 12 6 8montelukast. PFT changes over time are described in Table 1.
14/46 (30%) have died; with a median follow-up of 1.5 years
(range 0.13-3.97 years) from BO diagnosis, the median survival
from BO diagnosis has not been reached.
Conclusions: Patients receiving azithromycin in addition to stan-
dard therapy for BO maintained stable pulmonary function tests
for the first year following BO diagnosis. The generally favorable
survival following BO warrants further prospective research.310
THE ANCESTRAL HAPLOTYPE A1B8DR3 IS ASSOCIATED WITH IN-
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The 3 most common ancestral haplotypes in people of European
descent are A1B8DR3 (5.2%), A2B44DR4 (2.1%) and A3B7DR15
(2.6%). A1B8DR3 is associated with pulmonary autoimmune dis-
eases such as sarcoidosis and Wegener’s granulomatosis. Tumor
necrosis factor alpha (TNF-a) is the cytokine most frequently im-
plicated in the pathobiology of pulmonary complications after
HCT and TNF-a polymorphisms are strongly associated with
the A1B8DR3 haplotype. After observing several cases of pulmo-nary complications in A1B8DR3 patients, we conducted a retro-
spective cohort study to investigate the association of this
haplotype with pulmonary complications after allogeneic HCT.
From 1/1991 to 5/2005, 248 patients received an allogeneic
HCT from a related (N5 183) or unrelated (N5 65) peripheral
blood (n5 35) or marrow (n5 213) donor for myeloid (n5 159)
or lymphoid (n5 89) diseases. The A1B8DR3 haplotype was pres-
ent in 23 (9%), A2B44DR4 in 12 (5%) and A3B7DR15 in 19 (8%)
allogeneic HCT patients, which is higher than reported in normal
donors. Patient and treatment characteristics were: age at HCT 18-
40 years (n5 118, 48%), .40 years (n5 130, 52%); male (n5 155,
63%), European American (n5 234, 94%); KPS 90-100 (n5 159,
64%); VpCyTBI (n5 114), BuTBI (n5 27), BuCy (n5 27), Thio-
TBI (n5 22), CyTBI (n5 18); FluMel (n5 8); ThioCarbo (n5 8),
or Other (n5 24). Pulmonary complications included diffuse alve-
olar hemorrhage (DAH), bronchiolitis obliterans/lung GVHD
(BO/GVHD), viral or fungal pneumonia (VFPn), interstitial pneu-
monitis/ARDS/pleural effusion (IP/ARDS), and any one or more
of these pulmonary complications. There was no association of
A1B8DR3 with DAH or IP/ARDS, however BO/GVHD (17%
vs 4%, p5 0.017) and VFPn (30% vs 0%.p\0.001) were signifi-
cantly more common in patients with A1B8DR3. Any one or
more pulmonary complications was more common, but not signif-
icantly different, in patients with A1B8DR3 (48% vs 32%,
p5 0.16). Conversely, patients with the A2B44DR4 haplotype de-
veloped no pulmonary complications of any kind (0% vs 35%,
p5 0.013). There was no association of A3B7DR15 haplotype
with any pulmonary complications. There was no significant inter-
action for lymphoid/myeloid disease, related/unrelated donor or
male/female recipient between A1B8DR3 and any pulmonary com-
plications. Investigating the relationship between HLA haplotypeand outcome may improve our understanding of the pathogenesis
of pulmonary complications and provide individualized screening
and treatment for this adverse outcome.311
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LIMUS/SIROLIMUS AS GVHD PROPHYLAXIS
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We previously reported an encouraging result with RI-HCT
for MDS (Bone Marrow Transplant 2007) using fludarabine/mel-
phalan (Flu/Mel) conditioning and cyclosporine (CSA)/mycophe-
nolate (MMF) as GVHD prophylaxis. In order to further
improve upon the outcome in the RI-HCT setting, we initiated
a series of clinical trials at City of Hope designed to evaluate the
impact of tacrolimus (FK)/sirolimus (SIR)-based GVHD
